What the New HHS-Wide Nine-Application Cap Means for SBIR/STTR Companies
HHS will limit SBIR/STTR applicants to nine proposals annually, forcing companies to rethink submission volume and funding strategy.
On Fridays, any industry news that pertains to our services.
HHS will limit SBIR/STTR applicants to nine proposals annually, forcing companies to rethink submission volume and funding strategy.
Certain NIH and FDA components no longer accept clinical trials through Parent NOFOs, creating major application screening risks.
HHS Parent NOFOs now use a clinical trial optional structure, simplifying application selection while changing proposal strategy.
NIH SBIR/STTR funding is back, but applicants should pay close attention to new structures, requirements, and emerging signals.
Simpler.Grants.gov may reduce waiting time, but applicants delaying SAM.gov registration could still face devastating submission failures at deadline.
DOE’s SBIR/STTR overhaul signals a shift toward commercialization outcomes, faster pathways, and tighter alignment between innovation, labs, and market readiness.
SBIR/STTR has passed Congress and awaits signature. Use this short window to prepare strong proposals before solicitations return.
NIH removed the April 5 SBIR/STTR deadline because no active funding announcements exist. Future opportunities will appear first on Grants.gov.
Due to the absence of either a fiscal year 2026 appropriation or a Continuing Resolution for the Department of Health and Human Services, OLAW is now closed.
NIH clarifies the difference between Highlighted Topics and Funding Opportunities. Misunderstanding the distinction can undermine proposal success.